Brokerage firm Leerink Swann Maintains its rating on Alexion Pharmaceuticals(NASDAQ:ALXN). In a research note issued to the investors, the brokerage major Raises the price-target to $211.00 per share. The shares have been rated Outperform. The rating by Leerink Swann was issued on Sep 26, 2016.
In a different note, FBR Capital said it Initiates Coverage on Alexion Pharmaceuticals, according to a research note issued on Sep 15, 2016. The shares have been rated ‘Underperform’ by the firm. On Jul 29, 2016, Barclays said it Maintains its rating on Alexion Pharmaceuticals. In the research note, the firm Lowers the price-target to $165.00 per share. The shares have been rated ‘Equal-weight’ by the firm. RBC Capital said it Initiates Coverage on Alexion Pharmaceuticals, according to a research note issued on Jul 13, 2016. The shares have been rated ‘Outperform’ by the firm. On Jul 11, 2016, Credit Suisse said it Upgrades its rating on Alexion Pharmaceuticals. In the research note, the firm Lowers the price-target to $186.00 per share. The shares have been rated ‘Outperform’ by the firm.
Alexion Pharmaceuticals (ALXN) made into the market gainers list on Thursdays trading session with the shares advancing 2.55% or 3.33 points. Due to strong positive momentum, the stock ended at $133.69, which is also near the day’s high of $133.88. The stock began the session at $131.09 and the volume stood at 11,75,594 shares. The 52-week high of the shares is $193.45 and the 52 week low is $110.56. The company has a current market capitalization of $29,980 M and it has 22,42,48,000 shares in outstanding.
Alexion Pharmaceuticals(ALXN) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $753.12M. Analysts had an estimated revenue of $743.18M. Earnings per share were $1.13. Analysts had estimated an EPS of $1.18.
Several Insider Transactions has been reported to the SEC. On Sep 14, 2016, Carsten Thiel (EVP, Chief Commercial Officer) sold 3,225 shares at $126.60 per share price.Also, On Sep 9, 2016, Edward Miller (SVP, Chief Compliance Officer) sold 367 shares at $128.32 per share price.On Sep 2, 2016, Julie O’neill (EVP. Global Operations) sold 650 shares at $126.29 per share price, according to the Form-4 filing with the securities and exchange commission.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.